Published in Thyroid on July 01, 2008
Recombinant human TSH: the Argentinean experience. Thyroid (2009) 0.78
What role for recombinant human TSH in the treatment of metastatic thyroid cancer? Eur J Nucl Med Mol Imaging (2009) 0.77
Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. Biologics (2009) 0.77
Effects of recombinant human thyrotropin administration on 24-hour arterial pressure in female undergoing evaluation for differentiated thyroid cancer. Int J Endocrinol (2014) 0.75
Recombinant human thyrotropin use resulting in ovarian hyperstimulation: an unusual side effect. Eur Thyroid J (2014) 0.75
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab (2003) 3.24
Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med (1997) 2.20
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab (2002) 1.91
Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab (2007) 1.87
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab (2002) 1.81
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab (2003) 1.75
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45
Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab (2007) 1.25
A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab (2007) 1.23
Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer (2003) 1.17
Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med (2006) 1.10
Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid (2008) 1.09
Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol (2007) 1.06
Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol (2006) 1.05
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid (2001) 0.95
Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid (2006) 0.93
Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) (1985) 0.92
Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab (2000) 0.90
Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) (2006) 0.90
[Thyroid nodules and differentiated thyroid cancer: Brazilian consensus]. Arq Bras Endocrinol Metabol (2007) 0.89
The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid (2006) 0.87
Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest (1999) 0.84
Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. Minerva Endocrinol (2008) 0.81
How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nat Clin Pract Endocrinol Metab (2007) 0.81
Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid (2007) 0.80
Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Invest (1999) 0.80
Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when. Eur J Surg Oncol (2007) 0.78
Initial treatment of differentiated thyroid carcinoma. Rev Endocr Metab Disord (2000) 0.78
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid (2011) 7.17
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med (2012) 7.06
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Hypoglycemia and risk of death in critically ill patients. N Engl J Med (2012) 6.17
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Cardiac magnetic resonance with edema imaging identifies myocardium at risk and predicts worse outcome in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol (2010) 5.70
Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst (2005) 5.32
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
The clinical significance of subclinical thyroid dysfunction. Endocr Rev (2007) 3.80
Study protocol for the Fukushima Health Management Survey. J Epidemiol (2012) 3.67
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract (2011) 3.40
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol (2005) 3.20
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot (2006) 3.03
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid (2014) 2.77
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74
Optimizing nucleic acid extraction from thyroid fine-needle aspiration cells in stained slides, formalin-fixed/paraffin-embedded tissues, and long-term stored blood samples. Arq Bras Endocrinol Metabol (2012) 2.57
Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med (2008) 2.47
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab (2003) 2.44
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol (2013) 2.43
Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell (2010) 2.42
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci (2008) 2.39
Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg (2012) 2.35
Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab (2008) 2.30
Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet (2013) 2.25
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med (2012) 2.24
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
Assessment of the cost of fine-needle aspiration cytology as a diagnostic tool in patients with thyroid nodules. Am J Clin Pathol (2008) 2.18
Fine Needle Aspiration in the Investigation of Thyroid Nodules. Dtsch Arztebl Int (2016) 2.13
Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol Cell (2010) 2.09
Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ (2007) 2.07
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab (2007) 2.06
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. J Clin Endocrinol Metab (2011) 2.02
Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg (2015) 1.98
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res (2005) 1.91
Low plasma ghrelin levels in patients with Helicobacter pylori-associated gastritis. Am J Med (2004) 1.91
Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid (2009) 1.90
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab (2010) 1.86
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Dual oxidase2 is expressed all along the digestive tract. Am J Physiol Gastrointest Liver Physiol (2004) 1.84
Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol (2004) 1.82
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med (2008) 1.82
Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol (2002) 1.81
Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid (2014) 1.81
Interstage mortality after the Norwood procedure: Results of the multicenter Single Ventricle Reconstruction trial. J Thorac Cardiovasc Surg (2012) 1.79
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med (2004) 1.76
The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. Thyroid (2006) 1.76
New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol (2007) 1.74
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol (2011) 1.74
Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology (2007) 1.73
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid (2009) 1.73
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol (2010) 1.73
The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Hum Mol Genet (2010) 1.72
Early developmental outcome in children with hypoplastic left heart syndrome and related anomalies: the single ventricle reconstruction trial. Circulation (2012) 1.72
Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab (2007) 1.72
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72
Effect of Agouti-related protein in regulation of the hypothalamic-pituitary-thyroid axis in the melanocortin 4 receptor knockout mouse. Endocrinology (2004) 1.71
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery (2002) 1.71
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging (2003) 1.68
A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab (2002) 1.67
A rapid non-radioactive technique for measurement of repair synthesis in primary human fibroblasts by incorporation of ethynyl deoxyuridine (EdU). Nucleic Acids Res (2009) 1.66
Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab (2005) 1.64
Bone as a source of FGF23: regulation by phosphate? Bone (2004) 1.63
Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J Nucl Med (2005) 1.63
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab (2010) 1.63
Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation (2013) 1.62
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res (2009) 1.62
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab (2003) 1.61
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2013) 1.61